- Home
- ABEO vs CERS Comparison
ABEO vs CERS Comparison
Compare ABEO & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABEO
- CERS
- Stock Information
- Founded
- ABEO 1974
- CERS 1991
- Country
- ABEO United States
- CERS United States
- Employees
- ABEO N/A
- CERS N/A
- Industry
- ABEO Biotechnology: Pharmaceutical Preparations
- CERS EDP Services
- Sector
- ABEO Health Care
- CERS Technology
- Exchange
- ABEO Nasdaq
- CERS Nasdaq
- Market Cap
- ABEO 289.2M
- CERS 276.0M
- IPO Year
- ABEO 1980
- CERS 1997
- Fundamental
- Price
- ABEO $5.49
- CERS $1.58
- Analyst Decision
- ABEO Strong Buy
- CERS Strong Buy
- Analyst Count
- ABEO 6
- CERS 2
- Target Price
- ABEO $18.17
- CERS $3.50
- AVG Volume (30 Days)
- ABEO 1.0M
- CERS 1.6M
- Earning Date
- ABEO 11-13-2025
- CERS 11-05-2025
- Dividend Yield
- ABEO N/A
- CERS N/A
- EPS Growth
- ABEO N/A
- CERS N/A
- EPS
- ABEO 0.99
- CERS N/A
- Revenue
- ABEO $400,000.00
- CERS $192,510,000.00
- Revenue This Year
- ABEO N/A
- CERS $19.07
- Revenue Next Year
- ABEO $324.71
- CERS $12.03
- P/E Ratio
- ABEO $5.69
- CERS N/A
- Revenue Growth
- ABEO N/A
- CERS 13.25
- 52 Week Low
- ABEO $3.93
- CERS $1.12
- 52 Week High
- ABEO $7.54
- CERS $2.24
- Technical
- Relative Strength Index (RSI)
- ABEO 45.42
- CERS 55.71
- Support Level
- ABEO $5.21
- CERS $1.50
- Resistance Level
- ABEO $5.73
- CERS $1.70
- Average True Range (ATR)
- ABEO 0.24
- CERS 0.10
- MACD
- ABEO 0.06
- CERS -0.01
- Stochastic Oscillator
- ABEO 59.63
- CERS 50.00
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.